Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals has reported Total Non-Current Liabilities for 17 years, with the latest figure at $4.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 10.08% year-over-year to $4.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.0 billion (up 10.08% YoY), and the FY2025 full-year result was $4.2 billion, up 10.31% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $4.0 billion, down from $4.2 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $4.2 billion in Q3 2025, with the low at $2.9 billion in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $3.7 billion across 5 years, with a median of $3.7 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 29.54% — and 2025, when it slipped 1.28%.
• Alnylam Pharmaceuticals' Total Non-Current Liabilities stood at $3.5 billion in 2022, then gained by 7.16% to $3.7 billion in 2023, then advanced by 1.01% to $3.8 billion in 2024, then gained by 10.31% to $4.2 billion in 2025, then decreased by 2.95% to $4.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $4.0 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.2 billion (Q3 2025), per Business Quant data.